School of Basic Medicine, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250062, Shandong, China.
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, Shandong, China.
Biomed Pharmacother. 2022 Mar;147:112678. doi: 10.1016/j.biopha.2022.112678. Epub 2022 Feb 5.
The obesity epidemic has become a global public health crisis in recent years and is continuing to worsen at an alarming rate. However, the pathophysiological mechanisms involved in the development of obesity and obesity-related diseases are still being unraveled. In the past ten years, the gut microbiota has been identified as a crucial player affecting the onset and progression of obesity and obesity-related diseases, especially with respect to changes in its composition and metabolites during obesity progression. Herein, we summarize the roles and mechanisms of gut microbiota's composition and metabolite changes in the gut play in obesity and obesity related diseases. Furthermore, we discuss potential therapeutic treatments that can be used to modulate the gut microbiome composition and target the relevant metabolic pathways of obesity and obesity-related metabolic diseases.
近年来，肥胖症已成为全球公共健康危机，并以惊人的速度持续恶化。然而，肥胖症和肥胖相关疾病发展过程中涉及的病理生理机制仍在逐步揭示中。在过去的十年中，肠道微生物群已被确定为影响肥胖症和肥胖相关疾病发生和进展的关键因素，尤其是在肥胖症进展过程中其组成和代谢物的变化。在此，我们总结了肠道微生物群组成和代谢物变化在肥胖症和肥胖相关疾病中的作用和机制。此外，我们还讨论了潜在的治疗方法，这些方法可以用来调节肠道微生物群的组成，并针对肥胖症和肥胖相关代谢疾病的相关代谢途径。
